A 6-week-old infant receives his first dose of pentavalent vaccine (DTwP-HepB-Hib). Three hours later, he develops inconsolable high-pitched crying lasting 4 hours, which resolves spontaneously. He has no fever, no seizures, and no hypotonic-hyporesponsive episode. According to the Indian Academy of Pediatrics (IAP) and WHO guidelines, what is the correct action regarding the next scheduled pentavalent dose?

• A Permanently contraindicate all further pertussis-containing vaccines
• B Replace the whole-cell pertussis component with acellular pertussis (DTaP) for subsequent doses
• C Delay the next dose by 4 weeks and administer at a tertiary center under observation
• D Continue with scheduled pentavalent vaccine; persistent crying is a precaution, not a contraindication ✓

Explanation

Persistent inconsolable crying for ≥3 hours following a pertussis-containing vaccine (DTwP) is a recognized adverse event (AEFI) classified as a 'precaution' rather than a true contraindication per WHO and IAP guidelines. As an adverse event, it is self-limiting and does not predict neurological damage or severe adverse effects with subsequent doses. Per current IAP guidelines, this does NOT warrant permanent discontinuation of pertussis vaccination or switching to acellular pertussis. The child should continue with the scheduled pentavalent vaccine. True contraindications to further pertussis vaccine include encephalopathy within 7 days, anaphylaxis, and severe hypotonic-hyporesponsive episode. Parents should be counseled about the benign nature of this reaction.

Reference: Ghai Essential Pediatrics, 10th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.